Brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post earnings of ($0.32) per share for the current quarter, Zacks reports. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.38). Amicus Therapeutics reported earnings per share of ($0.33) in the same quarter last year, which indicates a positive year over year growth rate of 3%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that Amicus Therapeutics will report full year earnings of ($1.31) per share for the current financial year, with EPS estimates ranging from ($1.52) to ($1.18). For the next fiscal year, analysts forecast that the business will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.36) to ($0.65). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period last year, the firm earned ($0.40) earnings per share.

Several research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Chardan Capital upped their target price on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research note on Thursday, August 10th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research note on Monday, August 14th. Finally, Leerink Swann reissued an “outperform” rating and issued a $17.00 target price (down previously from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $15.25.

Amicus Therapeutics (NASDAQ FOLD) traded up 2.59% during trading on Friday, reaching $15.08. The company had a trading volume of 3,277,493 shares. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $16.06. The stock’s market cap is $2.48 billion. The firm has a 50-day moving average price of $13.24 and a 200 day moving average price of $9.90.

ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics, Inc. (FOLD) Expected to Announce Earnings of -$0.32 Per Share” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/30/amicus-therapeutics-inc-fold-expected-to-announce-earnings-of-0-32-per-share.html.

In other news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were purchased at an average cost of $12.25 per share, with a total value of $18,375,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.40% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in FOLD. Janus Henderson Group PLC acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $70,762,000. Wellington Management Group LLP lifted its position in shares of Amicus Therapeutics by 358.4% during the first quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock worth $38,083,000 after purchasing an additional 4,175,995 shares in the last quarter. Morgan Stanley lifted its position in shares of Amicus Therapeutics by 99.4% during the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after purchasing an additional 3,055,039 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Amicus Therapeutics during the first quarter worth approximately $21,394,000. Finally, Farallon Capital Management LLC acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $30,210,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.